Navigation Links
FDA Accepts Sanofi Pasteur's Application to Expand Indication of Menactra® Vaccine to Infants and Toddlers
Date:8/26/2010

SWIFTWATER, Pa., Aug. 26 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for use of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) for active immunization of infants and toddlers for the prevention of invasive meningococcal disease caused by serogroups A, C, Y, and W-135.

Menactra vaccine was the first quadrivalent conjugate vaccine licensed in the United States to help protect against meningococcal disease, a rare but serious disease that can take the life of a child within 24 hours.  Menactra vaccine is currently indicated for active immunization of individuals two through 55 years of age and is designed to help offer protection against four serogroups of Neisseria meningitidis (A, C, Y, and W-135), the bacterium that causes meningococcal infection.

The filing is based on results of one Phase II and three Phase III, open-label, controlled, multicenter trials, in which more than 3600 infants and toddlers from the United States received Menactra vaccine using a 2 dose schedule at 9 months and 12 months of age.  At 12 months Menactra vaccine was given concomitantly with either measles-mumps-rubella-varicella vaccine (MMRV), pneumococcal conjugate vaccine (PCV7), or Hepatitis A vaccine (HepA).  Results from the clinical studies show that a dose of Menactra vaccine at 9 and 12 months of age elicits a robust immune response against the serogroups included in the vaccine.  Responses to the concomitantly administered vaccines were equally robust.  Vaccine related reactions were similar to those described for other infant vaccines including swelling and tenderness at the site of vac
'/>"/>

SOURCE Sanofi Pasteur
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Talecris Biotherapeutics CEO Accepts 2010 Ernst & Young Entrepreneur Of The Year Award on Behalf of Employees and Patients
2. FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review
3. FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)
4. FDA Accepts Arno Therapeutics IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
5. Food and Drug Administration Accepts Isolagens Biologics License Application for Full Review
6. FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)
7. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
8. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
9. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
10. Sanofi-Aventis and Novalar File Marketing Authorization Application for OraVerse® in Five Key European Countries
11. Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Orameds Oral Insulin Capsules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Electrodes are devices that convert ionic ... to diagnose as well as treat several ailments ... facilitate the detection of chemical reactions derived from ... of the patients. In addition, few electrodes such ... to perform minimally invasive surgical procedures. The electrodes ...
(Date:10/30/2014)... 29, 2014 The global market for ... the introduction of new vaccines. These new products ... World Market. The Kalorama information report examines the ... and developmental vaccines for diseases that are already ... also entire communities from diseases spread by person-to-person ...
(Date:10/27/2014)... ZURICH , 27 de octubre de 2014 ... a menudo conocida como ardor de estómago, es ... el mundo. [1] La elección de alimentos ... tener un impacto en los síntomas de la ... para ayudar a las personas a gestionar los ...
Breaking Medicine Technology:Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 2Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 3Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 4Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 2Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 3Trate los síntomas del reflujo gracias a la Food4GERD App 2Trate los síntomas del reflujo gracias a la Food4GERD App 3Trate los síntomas del reflujo gracias a la Food4GERD App 4
... Volcano Corporation (Nasdaq: VOLC ) announced today the completion of the first ... performed in seven centers within the United States . Commercial launch of Eagle ... , , ... , , ...
... , SAN DIEGO , May 20 ... announced today that the U.S. Patent and Trademark Office has ... microfluidic device. U.S. patent #7,695,956 entitled "Device for Cell Separation ... to isolate cells from a bodily fluid using a flow ...
Cached Medicine Technology:Physicians Cite Positive First Clinical Experience with Volcano's Eagle Eye® Platinum Digital IVUS Catheter 2Physicians Cite Positive First Clinical Experience with Volcano's Eagle Eye® Platinum Digital IVUS Catheter 3Physicians Cite Positive First Clinical Experience with Volcano's Eagle Eye® Platinum Digital IVUS Catheter 4Biocept, Inc. Announces Issuance of Patent for its Microfluidic Technology 2
(Date:10/30/2014)... 30, 2014 Home Care Assistance – ... of non-medical, in-home senior care, is weighing in on ... health. , The study, performed by the University of ... and 78 over a week-long period and observed how ... physical activity. By examining the structural soundness of the ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Horse ... therapeutic horseback riding to special needs individuals in the ... on Saturday, November 15 from 10-2:00 p.m. at Bailey's ... is open to the public and is designed to ... , Admission to the HSS Round-Up is free. Ticket ...
(Date:10/30/2014)... 30, 2014 USARAD Holdings ... teleradiology and specialty telemedicine solutions provider, including ... its existing teleradiology services at Mission Bend ER, ... expert telemedicine services, to the state-of-the-art, 24/7, freestanding ... result of this innovative partnership, there will be ...
(Date:10/30/2014)... Carolina (PRWEB) October 30, 2014 The ... should be more vigorously exercised to help maintain better ... authored the book ‘Dementia Express: Lose Your Memory in ... uses counterintuitive reasoning and sometimes conflicting attitudes to help ... for the mind, a reader must decipher the hidden ...
(Date:10/30/2014)... October 30, 2014 Victory Healthcare, ... its 2014 third quarter infection rates and patient ... infection rates of only two percent or less, ... scores exceeding 98 percent. , “We are delighted ... included rising satisfaction scores,” said Robert Helms, chairman ...
Breaking Medicine News(10 mins):Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 3Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 3Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3
... , THURSDAY, June 30 (HealthDay News) -- Illegal ... the United States as the result of a historic federal ... The average national retailer violation rate in 2010 was 9.3 ... federal program that requires states and U.S. jurisdictions to have ...
... could hold the key to people giving up smoking after ... smokers doubled quit rates at six months. , The findings ... School of Hygiene & Tropical Medicine and funded by the ... today. , Text messaging is an innovative approach to the ...
... , WEDNESDAY, June 29 (HealthDay News) -- Outpatient ... occur in manual systems, a new study finds. ... pharmacy chain in three different U.S. states over a ... 12 percent) contained a total of 466 errors, of ...
... Lung Screening Trial (NLST) published online in the June ... a twenty percent reduction in lung cancer deaths among ... tomography (CT) versus those screened with chest X-ray. Conducted ... and the National Cancer Institute,s Lung Screening Study Group, ...
... Current and former heavy smokers can now be screened ... Lung Screening Trial (NLST) revealed that detecting small lung ... mortality by 20 percent. Prior to the ... of the disease, had shown no benefit from screening ...
... Mozes HealthDay Reporter , WEDNESDAY, June 29 ... researcher was mysteriously, and fatally, infected with the black ... of the microbe. Now, a follow-up investigation has ... predisposition that made him vulnerable to the hazards of ...
Cached Medicine News:Health News:Illegal Tobacco Sales to U.S. Minors Reach All-Time Low 2Health News:Text message support for smokers doubles quit rates 2Health News:E-Prescribing Doesn't Slash Errors, Study Finds 2Health News:Lung cancer screening trial shows screening with CT scans reduces lung cancer deaths 2Health News:Lung cancer screening trial shows screening with CT scans reduces lung cancer deaths 3Health News:UT MD Anderson debuts lung cancer screening program 2Health News:UT MD Anderson debuts lung cancer screening program 3Health News:U.S. Plague Fatality 'Isolated' Lab Incident, New Report Confirms 2Health News:U.S. Plague Fatality 'Isolated' Lab Incident, New Report Confirms 3
The DBIL method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of direct (conjugated) bilirubin in serum and plasma....
For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum...
Latex agglutination slide test for the qualitative and semi-quantitative determination of Anti-Streptolysin O (ASO) in human serum...
For the quantitative in vitro determination of IgA in serum and plasma. This product is suitable for use on Hitachi 704, 705, 717, 902, 911 and 912....
Medicine Products: